2021 年 2 月至 5 月，美国≥16 岁有症状门诊患者中信使 RNA 疫苗对 2019 年冠状病毒病的有效性。
Messenger RNA Vaccine Effectiveness Against Coronavirus Disease 2019 Among Symptomatic Outpatients Aged ≥16 Years in the United States, February-May 2021.
机构信息
Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
出版信息
J Infect Dis. 2021 Nov 22;224(10):1694-1698. doi: 10.1093/infdis/jiab451.
Abstract
Evaluations of vaccine effectiveness (VE) are important to monitor as coronavirus disease 2019 (COVID-19) vaccines are introduced in the general population. Research staff enrolled symptomatic participants seeking outpatient medical care for COVID-19-like illness or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing from a multisite network. VE was evaluated using the test-negative design. Among 236 SARS-CoV-2 nucleic acid amplification test-positive and 576 test-negative participants aged ≥16 years, the VE of messenger RNA vaccines against COVID-19 was 91% (95% confidence interval, 83%-95%) for full vaccination and 75% (55%-87%) for partial vaccination. Vaccination was associated with prevention of most COVID-19 cases among people seeking outpatient medical care.
摘要
评估疫苗有效性（VE）很重要，因为 2019 年冠状病毒病（COVID-19）疫苗将在普通人群中推出。研究人员从多地点网络招募了有症状的参与者，这些参与者因 COVID-19 样疾病或严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）检测而寻求门诊医疗。使用阴性检测设计评估 VE。在 236 名 SARS-CoV-2 核酸扩增检测阳性和 576 名检测阴性、年龄≥16 岁的参与者中，针对 COVID-19 的信使 RNA 疫苗的完全接种 VE 为 91%（95%置信区间，83%-95%），部分接种 VE 为 75%（55%-87%）。接种疫苗与预防大多数在门诊就医的人发生 COVID-19 病例有关。
相似文献
1
Messenger RNA Vaccine Effectiveness Against Coronavirus Disease 2019 Among Symptomatic Outpatients Aged ≥16 Years in the United States, February-May 2021.2021 年 2 月至 5 月，美国≥16 岁有症状门诊患者中信使 RNA 疫苗对 2019 年冠状病毒病的有效性。
J Infect Dis. 2021 Nov 22;224(10):1694-1698. doi: 10.1093/infdis/jiab451.
2
Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021-February 2022.2021 年 10 月至 2022 年 2 月期间，两剂和三剂 mRNA COVID-19 疫苗对奥密克戎和德尔塔相关成人门诊疾病的有效性。
Influenza Other Respir Viruses. 2022 Nov;16(6):975-985. doi: 10.1111/irv.13029. Epub 2022 Jul 29.
3
Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States.严重急性呼吸综合征冠状病毒 2 信使 RNA 疫苗预防美国 2019 年冠状病毒病住院的效果。
Clin Infect Dis. 2022 May 3;74(9):1515-1524. doi: 10.1093/cid/ciab687.
4
Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS).信使 RNA 新冠肺炎疫苗在日本德尔塔变异株流行期间针对有症状的严重急性呼吸综合征冠状病毒 2 感染的有效性：实时监测针对 SARS-CoV-2 的疫苗有效性 (VERSUS)。
Clin Infect Dis. 2022 Nov 30;75(11):1971-1979. doi: 10.1093/cid/ciac292.
5
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.辉瑞-生物科技和 Moderna 疫苗在 SARS-CoV-2 B.1.617.2（Delta）变异株广泛传播之前和期间预防养老院居民感染 SARS-CoV-2 的有效性 - 国家医疗保健安全网络，2021 年 3 月 1 日至 8 月 1 日。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.
6
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.早期估计，二价 mRNA 加强针在预防免疫功能正常成年人因奥密克戎 BA.5-和 XBB/XBB.1.5 相关亚谱系导致的有症状 SARS-CoV-2 感染方面的有效性-增加社区获得检测计划，美国，2022 年 12 月至 2023 年 1 月。
MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):119-124. doi: 10.15585/mmwr.mm7205e1.
7
Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States.美国 Delta 和奥密克戎变异株流行期间估计 COVID-19 mRNA 疫苗在孕妇中对有医疗需要的 COVID-19 的有效性。
JAMA Netw Open. 2022 Sep 1;5(9):e2233273. doi: 10.1001/jamanetworkopen.2022.33273.
8
Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada.一剂 mRNA 疫苗对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）、包括阿尔法和伽马变异株的有效性：加拿大不列颠哥伦比亚省 70 岁及以上成年人的阴性检测设计。
Clin Infect Dis. 2022 Apr 9;74(7):1158-1165. doi: 10.1093/cid/ciab616.
9
Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).新型冠状病毒病 19（COVID-19）疫苗对日本德尔塔主导和奥密克戎主导期间有症状的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的有效性：一项多中心前瞻性病例对照研究（与 SARS-CoV-2 感染相关的因素和 COVID-19 疫苗的有效性研究）。
Clin Infect Dis. 2023 Feb 8;76(3):e108-e115. doi: 10.1093/cid/ciac635.
10
Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3-5 Years - Increasing Community Access to Testing Program, United States, July 2022-February 2023.3-5 岁儿童中单价 mRNA 疫苗预防有症状 SARS-CoV-2 感染的有效性初步估计-增加社区检测计划，美国，2022 年 7 月至 2023 年 2 月。
MMWR Morb Mortal Wkly Rep. 2023 Feb 17;72(7):177-182. doi: 10.15585/mmwr.mm7207a3.
引用本文的文献
1
Time-varying effects of COVID-19 vaccination on symptomatic and asymptomatic infections in a prospective university cohort in the USA.美国一所大学前瞻性队列研究中COVID-19疫苗接种对有症状和无症状感染的时变效应。
BMJ Open. 2025 Feb 22;15(2):e084408. doi: 10.1136/bmjopen-2024-084408.
2
Prior infections and effectiveness of SARS-CoV-2 vaccine in test-negative studies: a systematic review and meta-analysis.SARS-CoV-2疫苗在检测阴性研究中的既往感染情况及有效性：一项系统评价和荟萃分析
Am J Epidemiol. 2024 Dec 2;193(12):1868-1881. doi: 10.1093/aje/kwae142.
3
Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021.美国 2020 年 12 月至 2021 年 9 月，疫苗接种者预防 COVID-19 感染、住院和死亡人数的估计数。
JAMA Netw Open. 2022 Jul 1;5(7):e2220385. doi: 10.1001/jamanetworkopen.2022.20385.
4
Vaccine effectiveness against COVID-19 among symptomatic persons aged ≥12 years with reported contact with COVID-19 cases, February-September 2021.2021 年 2 月至 9 月，≥12 岁有报告接触过 COVID-19 病例的有症状者中，针对 COVID-19 的疫苗有效性。
Influenza Other Respir Viruses. 2022 Jul;16(4):673-679. doi: 10.1111/irv.12973. Epub 2022 Feb 15.
Zotero 插件